Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
43/100
While Alzheimer's disease and other neurodegenerative diseases have traditionally been viewed as brain disorders, there is growing evidence indicating their manifestation in the eyes as well.
-
The amyloid beta (Aβ) 42/40 ratio has been widely studied as a biomarker in Alzheimer's disease (AD); however, other Aβ peptides could also represent relevant biomarkers.
-
Blood biomarkers are minimally invasive, are available at a relatively low cost, and are easily accessible; therefore, they are expected to play a pivotal role in the diagnosis of dementia.
-
Alzheimer's disease (AD) is the leading cause of dementia worldwide.
-
In total, 371 eyes of 249 control subjects and 75 eyes of 52 PD subjects were used for training, validation, and testing.
-
47 retired contact sport athletes negative for AD (age:51 ± 14; concussions/athlete:15 ± 2) and 54 normal controls (age:50 ± 13) were included.
-
Dementia is a group of symptoms including memory loss, language difficulties, and other types of cognitive and functional impairments that affects 57 million people worldwide, with the incidence expected to double by 2040.
-
43/100
This commentary article delves into the transformative role of optical coherence tomography angiography (OCTA) in diagnosing and managing a wide array of eye conditions, including diabetic retinopathy, age-related macular degeneration, retinal vein occlusions, and white dot syndromes.
-
Neurological damage is the pathological substrate of permanent disability in various neurodegenerative disorders.
-
Neurodegenerative disorders such as Alzheimer's disease (AD) represent an increasingly significant public health concern.
-
The retina is an emerging CNS target for potential noninvasive diagnosis and tracking of Alzheimer's disease (AD).
-
The synaptic proteins revealed no statistically significant differences between BD and HC, neither at baseline, one-year follow-up, or in terms of changes from baseline to follow-up.
-
Recent technological advances have improved the sensitivity and specificity of blood-based biomarkers for Alzheimer's disease and related dementias.
-
43/100
An extensive exploration of lacrimal fluid molecular biomarkers in understanding and diagnosing a spectrum of ocular and systemic diseases is presented.
-
This paper introduces a new deep learning-assisted offline smartphone platform for early AD screening, offering rapid disease detection in low-resource areas.
-
The escalating prevalence of Alzheimer's disease (AD) highlights the urgent need to develop reliable biomarkers for early diagnosis and intervention.
-
Glaucoma is a group of optic neuropathies and the world's leading cause of irreversible blindness.
-
Alzheimer's disease (AD) is a serious dementia afflicting aging population and is characterized by cognitive decline, amyloid-β plaques, and neurofibrillary tangles.
-
Amyloid beta 1-40 (Aβ 1-40) is one of the most abundant substances in the body with the capacity to form insoluble aggregates and is a universal biomarker for the prediction of Alzheimer's disease.
-
The levels of p-tau217 and p-tau231 in cerebrospinal fluid (CSF) are associated with early amyloid beta (Aß) changes in the brain, while the CSF levels of p-tau205 are foremost related to tau pathology in the later stages of the disease.
-
Dementia represents a growing public health burden with large social, racial, and ethnic disparities.
-
Major depressive disorder (MDD) is a prevalent brain disorder affecting more than 2% of the world's population.
-
43/100
Plasma p-tau231 showed a significant rate of change over time.
-
Ethics Review began a decade ago with a mission to identify ethical concerns that hold back innovation and to promote solutions that would move the field forward.
-
As our knowledge about the biology of Alzheimer's disease (AD) expands and we recognize the significance of early intervention for effective treatment, there is a shift in focus toward detecting the disease at an early stage.
From across this topic
10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Increased neurofilament light chain blood levels in neurodegenerative neurological diseases
- Amyloid-β as a Blood Biomarker for Alzheimer's Disease: A Review of Recent Literature
- Plasma biomarkers predict Alzheimer's disease before clinical onset in Chinese cohorts
- Plasma ATN(I) classification and precision pharmacology in Alzheimer's disease
- Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease
- Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability
- Refining Alzheimer's disease biological diagnosis with plasma biomarkers: Resolving p-tau217 "gray zone" with p-tau181 integration
- Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome
- CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease
- Discovering the Italian phenotype of cerebral amyloid angiopathy (CAA): the SENECA project